Nuvalent, Inc. (NUVL) presented positive data from its Phase 1/2 trials of zidesamtinib (ARROS-1) and NVL-655 (ALKOVE-1) at the European Society for Medical Oncology (ESMO) Congress 2024. The data showcased significant response rates and durable responses in heavily pretreated patients with advanced ROS1-positive and ALK-positive non-small cell lung cancer (NSCLC) and other solid tumors. Nuvalent plans to initiate a Phase 3 study for ALK-positive NSCLC in the first half of 2025.
Psyence Biomedical, a biotechnology company focused on natural psychedelic-based solutions for mental health, has announced significant progress in its clinical trials and partnerships. The company is currently conducting a Phase IIb clinical trial in Australia for psilocybin-assisted therapy for Adjustment Disorder in palliative care and is expanding its pipeline into Substance Use Disorders, particularly Alcohol Use Disorder (AUD). These developments position Psyence for key data readouts in 2025, potentially leading to commercial success.
The FDA has approved Eli Lilly’s Ebglyss (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for adults and children with moderate-to-severe atopic dermatitis (eczema) that doesn’t respond well to topical treatments. Ebglyss targets eczema inflammation throughout the body, leading to significant improvement in skin dryness, itching, and irritation. The drug’s effectiveness was proven in clinical trials, with a substantial percentage of patients achieving clear or almost-clear skin and itch relief.
Influencer Fabiana Justus, diagnosed with Acute Myeloid Leukemia earlier this year, continues to share her journey through treatment following a bone marrow transplant. In recent videos, she updates her followers on her progress, including a new round of tests at the hospital and the challenges she faces with ongoing medication.
Ascendis Pharma A/S (ASND) announced positive topline data from a Phase 3 trial of TransCon CNP (navepegritide) for children with achondroplasia, a genetic disorder causing dwarfism. The investigational drug demonstrated significant improvement in growth velocity compared to placebo, leading to a potential FDA application in the first quarter of 2025.
The global fetal Doppler market is experiencing robust growth, driven by technological advancements, increasing demand for prenatal care, and the rising prevalence of pregnancy-related complications. Wireless technologies, improved probe accuracy, and enhanced portability are making fetal Doppler devices more accessible and user-friendly, leading to increased adoption in both clinical and home settings. The market is expected to reach US$ 488.3 million by 2034, with North America dominating the region.
Bayer AG announced positive results from the Phase 3 ARANOTE trial for darolutamide, demonstrating a significant reduction in the risk of disease progression or death in patients with metastatic hormone-sensitive prostate cancer (mHSPC). These findings could lead to expanded use of darolutamide for mHSPC patients.
Epitomee Medical Ltd. has received FDA clearance for its innovative Epitomee® Capsule, a drug-free, ingestible device designed to support weight management in adults with a BMI of 25-40. This groundbreaking technology offers a new option for individuals seeking safe and effective weight loss solutions.
A new study reveals that university freshers spend an average of 13 days partying in their first year, with many neglecting their health and risking hearing damage. The research, commissioned by Specsavers, highlights the importance of hearing protection and the potential consequences of excessive noise exposure.
The Chuseok holiday in Korea sees a surge in international patients seeking cosmetic surgery, particularly stem cell-based procedures. Driven by K-Beauty trends and advanced technology, Korean clinics offer natural, long-lasting results, attracting patients from Japan, China, and the US.
